| Q44145529 | A pilot case control follow-up study on hearing in children treated with tobramycin in the newborn period |
| Q44304124 | Amikacin alters auditory brainstem conduction time in newborns |
| Q38181171 | Aminoglycoside toxicity in neonates: something to worry about? |
| Q38676819 | Aminoglycoside-induced hearing loss in humans |
| Q50582560 | Aminoglycosides and neonatal deafness. |
| Q41429391 | Antibacterial therapy in pregnancy and neonates. |
| Q50555523 | Auditory function after continuous infusion of gentamicin to high-risk newborns. |
| Q33541660 | Etiology of hearing loss in children. Nongenetic causes |
| Q40594113 | Experimental, clinical and preventive aspects of ototoxicity |
| Q40541075 | Failure to clinically predict NICU hearing loss |
| Q46488798 | Gentamicin use in neonates: should we have a change of practice? |
| Q50498817 | Otoacoustic emissions--an approach for monitoring aminoglycoside induced ototoxicity in children. |
| Q38015214 | Review of a high risk register for congenital or early-onset deafness |
| Q50518931 | Risk factors for sensorineural hearing loss in extremely premature infants |
| Q38821699 | The amikacin research program: a stepwise approach to validate dosing regimens in neonates. |